These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 17564637)

  • 1. A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation.
    Vincenti F; Mendez R; Pescovitz M; Rajagopalan PR; Wilkinson AH; Butt K; Laskow D; Slakey DP; Lorber MI; Garg JP; Garovoy M
    Am J Transplant; 2007 Jul; 7(7):1770-7. PubMed ID: 17564637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LFA-1 (CD11a) as a therapeutic target.
    Nicolls MR; Gill RG
    Am J Transplant; 2006 Jan; 6(1):27-36. PubMed ID: 16433753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-adhesion antibodies efalizumab, a humanized anti-CD11a monoclonal antibody.
    Dedrick RL; Walicke P; Garovoy M
    Transpl Immunol; 2002 May; 9(2-4):181-6. PubMed ID: 12180828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New monoclonal antibodies in renal transplantation.
    Vincenti F
    Minerva Urol Nefrol; 2003 Mar; 55(1):57-66. PubMed ID: 12773967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody.
    Gottlieb AB; Krueger JG; Wittkowski K; Dedrick R; Walicke PA; Garovoy M
    Arch Dermatol; 2002 May; 138(5):591-600. PubMed ID: 12020219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The lymphocyte: protagonism in the new era of the biological therapies].
    Gutiérrez M; Ruiz Carrascosa JC
    Actas Dermosifiliogr; 2008 Jan; 99 Suppl 1():2-8. PubMed ID: 18341848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma.
    Gauvreau GM; Becker AB; Boulet LP; Chakir J; Fick RB; Greene WL; Killian KJ; O'byrne PM; Reid JK; Cockcroft DW
    J Allergy Clin Immunol; 2003 Aug; 112(2):331-8. PubMed ID: 12897739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efalizumab.
    Wellington K; Perry CM
    Am J Clin Dermatol; 2005; 6(2):113-8; discussion 119-20. PubMed ID: 15799683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis.
    Joshi A; Bauer R; Kuebler P; White M; Leddy C; Compton P; Garovoy M; Kwon P; Walicke P; Dedrick R
    J Clin Pharmacol; 2006 Jan; 46(1):10-20. PubMed ID: 16397279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis.
    Stratta RJ; Alloway RR; Hodge E; Lo A;
    Clin Transplant; 2002 Feb; 16(1):60-8. PubMed ID: 11982617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of therapeutic integrin (CD11a) blockade with efalizumab on immune responses to model antigens in humans: results of a randomized, single blind study.
    Krueger JG; Ochs HD; Patel P; Gilkerson E; Guttman-Yassky E; Dummer W
    J Invest Dermatol; 2008 Nov; 128(11):2615-2624. PubMed ID: 18496564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efalizumab modulates T cell function both in vivo and in vitro.
    Koszik F; Stary G; Selenko-Gebauer N; Stingl G
    J Dermatol Sci; 2010 Dec; 60(3):159-66. PubMed ID: 21044829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Administration of an anti-CD11a monoclonal antibody in recipients of kidney transplantation. A pilot study.
    Hourmant M; Le Mauff B; Le Meur Y; Dantal J; Cantarovich D; Giral M; Caudrelier P; Albericci G; Soulillou JP
    Transplantation; 1994 Aug; 58(3):377-80. PubMed ID: 8053064
    [No Abstract]   [Full Text] [Related]  

  • 14. Topo-proteomic in situ analysis of psoriatic plaque under efalizumab treatment.
    Bonnekoh B; Pommer AJ; Böckelmann R; Hofmeister H; Philipsen L; Gollnick H
    Skin Pharmacol Physiol; 2007; 20(5):237-52. PubMed ID: 17587888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Balancing immunity and immunosuppression: vaccinating patients receiving treatment with efalizumab.
    Marmon S; Strober BE
    J Invest Dermatol; 2008 Nov; 128(11):2567-2569. PubMed ID: 18927537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized multicenter trial comparing leukocyte function-associated antigen-1 monoclonal antibody with rabbit antithymocyte globulin as induction treatment in first kidney transplantations.
    Hourmant M; Bedrossian J; Durand D; Lebranchu Y; Renoult E; Caudrelier P; Buffet R; Soulillou JP
    Transplantation; 1996 Dec; 62(11):1565-70. PubMed ID: 8970608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis.
    Gottlieb A; Krueger JG; Bright R; Ling M; Lebwohl M; Kang S; Feldman S; Spellman M; Wittkowski K; Ochs HD; Jardieu P; Bauer R; White M; Dedrick R; Garovoy M
    J Am Acad Dermatol; 2000 Mar; 42(3):428-35. PubMed ID: 10688712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific immunosuppression of corneal allograft rejection by combination of anti-VLA-4 and anti-LFA-1 monoclonal antibodies in mice.
    Hori J; Isobe M; Yamagami S; Mizuochi T; Tsuru T
    Exp Eye Res; 1997 Jul; 65(1):89-98. PubMed ID: 9237869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of cardiac allografts with established leukocyte infiltration by modulation of alpha4 (CD49d) and leukocyte function-associated antigen-1 (CD11a/CD18) integrin function.
    Chan BM; Zheng H; Wang H; Uniyal S; Garcia B; Wang J; Zhong R
    Transplantation; 1998 Aug; 66(3):277-83. PubMed ID: 9721793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.
    Lebwohl M; Tyring SK; Hamilton TK; Toth D; Glazer S; Tawfik NH; Walicke P; Dummer W; Wang X; Garovoy MR; Pariser D;
    N Engl J Med; 2003 Nov; 349(21):2004-13. PubMed ID: 14627785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.